Pharsight

1. List of Pyrukynd drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8785450	AGIOS PHARMS INC	Therapeutic compounds and compositions	Feb, 2031 (8 years from now)
US11254652	AGIOS PHARMS INC	Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide	Nov, 2038 (15 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682080	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	May, 2032 (9 years from now)
US9980961	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	May, 2032 (9 years from now)
US10632114	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	May, 2032 (9 years from now)
US9193701	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	Oct, 2032 (9 years from now)
US11234976	AGIOS PHARMS INC	Methods of using pyruvate kinase activators	Oct, 2038 (15 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 17, 2027

NCE-1 date: February, 2026

Market Authorisation Date: 17 February, 2022

Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency by administering a daily dose of 10mg to 100mg

Dosage: TABLET;ORAL